Qorvo, Inc.
QRVOQorvo, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +524.1% against a +13.0% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (2 weeks in). Underneath, the last four quarters read mixed — profit +0.0% year on year, and 454% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Qorvo, Inc. trades at $95.0, in a confirmed uptrend and 2 weeks into that stage. That is +9.2% against its own 200-day average. It sits at 61% of a 52-week range of $77 to $106. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 2 of stage 2. At $95.0 it trades +9.2% versus its 200-day average and sits at 61% of its 52-week range ($77–$106).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +70% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Qorvo, Inc. trades at 22.0× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.0× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +524.1% against a +13.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the −3.8%/yr price move, ~+57.9%/yr came from earnings growth and ~−61.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Qorvo, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −1.1% | +1.0% | — | — |
| Profit | +466.7% | +50.4% | — | — |
| EPS | +524.1% | +53.5% | — | — |
| Stock price | +13.0% | −3.8% | −13.4% | +5.6% |
4-Factor Sector Score
41.9/100 — rank 20 of 27 in Semiconductors · 56% evidence confidence
Qorvo, Inc. scores 41.9 out of 100 against the 27 companies it is compared with in Semiconductors, ranking 20. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.2 + 7.1 + 11.4 + 7.2 = 41.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Qorvo, Inc. reported $0.8 B of revenue in the Mar 26 quarter, −6.9% year on year. Over 4 years it has compounded at −5.7% a year. The last full year, FY26, came in at $3.7 B. The last four reported quarters add to $3.7 B.
FY26 revenue came in at $3.7 B (−1.1% on the year), capping 4 years at −5.7% compound. The latest quarter (Mar 26) printed $0.8 B, −6.9% year on year.
Pace check: the last four quarters averaged −1.6% growth against the decade's −5.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −1.3% over the last 4 quarters against −1.1%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Qorvo, Inc.'s operating margin is 3.7% in the Mar 26 quarter, +0.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.4% to 26.5%. The current quarter sits inside that band.
The latest quarter's operating margin is 3.7%, +0.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 2.4%–26.5%.
Why the margin moved: operating margin went +0.3 pp year on year while gross margin went +6.9 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Qorvo, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.3 B. The 4-year compound rate is −24.2%. That is 3.7% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY26 printed $0.3 B (+466.7%), and the 4-year compound rate is −24.2%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 454% of Qorvo, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.8 B of operating cash against $0.3 B of profit. After $0.1 B of capital spending, $0.7 B was left as free cash.
FY26: operating cash of $0.8 B against reported profit of $0.3 B, leaving free cash of $0.7 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 454% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Qorvo, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Qorvo, Inc. earns a ROE of 10% in FY26. That is up from a trough of −2% in FY24. Return on invested capital clears the cost of that capital by +3.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 9.2% net margin on 0.63× asset turns.
FY26 ROE is 10%, recovered from a FY24 trough of −2% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.2% net margin × 0.63× asset turns × 1.75× balance-sheet leverage ≈ 10.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 14.7% − 10.9% = a +3.8 pp spread. The 10.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
Qorvo, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Qorvo, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Qorvo, Inc. carries total debt of $1.6 B against shareholder equity of $3.5 B as of Jun 26, a debt-to-equity of 0.45. On the annual view that ratio went from 0.45 in FY22 to 0.46 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $1.6 B against shareholder equity of $3.5 B — a debt-to-equity of 0.45. On the annual view, debt-to-equity went from 0.45 (FY22) to 0.46 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
8.5% of Qorvo, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 8.5% of the float is sold short, and at typical trading volumes it would take about 5.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Qorvo, Inc.: the Z-score reads 3.31. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.31 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.31.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Micron Technology, Inc.MU | 74.0/100Favorable setup71% evidence | LEADER | 28.4/35 Revenue 100% · PAT 100% · OPM change 57.1 pp 83% evidence | 19.5/25 ROCE 36.4% · OPM 80.4% 76% evidence | 11.5/20 P/E 20.9× · PEG — 15% evidence | 14.6/20 RS sector 49.3% · RS bench 78.5% · 1Y 650.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.4 + 19.5 + 11.5 + 14.6 = 74 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NVIDIA CorporationNVDA | 72.3/100Favorable setup81% evidence | ASLEEP | 28.0/35 Revenue 70.7% · PAT 100% · OPM change 16.5 pp 83% evidence | 21.3/25 ROCE 34.1% · OPM 65.6% 76% evidence | 15.1/20 P/E 31.9× · PEG 0.79 65% evidence | 7.9/20 RS sector -27.2% · RS bench 0.2% · 1Y 16%4 of 12 weeks ahead 100% evidence |
| Exact sum: 28 + 21.3 + 15.1 + 7.9 = 72.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Credo Technology Group Holding LtdCRDO | 64.9/100Mixed-positive evidence71% evidence | LEADER | 26.2/35 Revenue 100% · PAT 100% · OPM change 15.8 pp 83% evidence | 14.1/25 ROCE 11.1% · OPM 35.7% 76% evidence | 9.8/20 P/E 73.5× · PEG — 15% evidence | 14.8/20 RS sector -0.5% · RS bench 32.5% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.2 + 14.1 + 9.8 + 14.8 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Silicon Motion Technology CorporationSIMO | 63.5/100Thin evidence · provisional56% evidence | FADING | 22.5/35 Revenue — · PAT — · OPM change 9.4 pp 39% evidence | 15.6/25 ROCE 10.3% · OPM 15.3% 76% evidence | 10.7/20 P/E 39.1× · PEG — 15% evidence | 14.7/20 RS sector 29.7% · RS bench 60.2% · 1Y 251.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 15.6 + 10.7 + 14.7 = 63.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Astera Labs, Inc.ALAB | 62.2/100Thin evidence · provisional56% evidence | LEADER | 22.8/35 Revenue 100% · PAT 100% · OPM change 13 pp 53% evidence | 11.3/25 ROCE 4.8% · OPM 20.1% 57% evidence | 9.7/20 P/E 74.1× · PEG — 15% evidence | 18.4/20 RS sector 19.9% · RS bench 56.4% · 1Y 101.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 11.3 + 9.7 + 18.4 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Advanced Micro Devices, Inc.AMD | 58.4/100Thin evidence · provisional56% evidence | LEADER | 20.0/35 Revenue 35% · PAT 100% · OPM change 3.6 pp 53% evidence | 10.9/25 ROCE 2.2% · OPM 14.4% 57% evidence | 10.0/20 P/E 66× · PEG — 15% evidence | 17.5/20 RS sector 28.7% · RS bench 62.4% · 1Y 200.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 10.9 + 10 + 17.5 = 58.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Texas Instruments IncorporatedTXN | 57.4/100Thin evidence · provisional56% evidence | FADING | 19.9/35 Revenue — · PAT — · OPM change 5 pp 39% evidence | 15.6/25 ROCE 7.1% · OPM 37.5% 76% evidence | 10.5/20 P/E 45.4× · PEG — 15% evidence | 11.4/20 RS sector -12.4% · RS bench 16.3% · 1Y 51.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.9 + 15.6 + 10.5 + 11.4 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Lattice Semiconductor CorporationLSCC | 55.2/100Thin evidence · provisional56% evidence | FADING | 20.7/35 Revenue — · PAT — · OPM change 11.5 pp 39% evidence | 11.6/25 ROCE 3.4% · OPM 15.3% 76% evidence | 8.6/20 P/E 678.7× · PEG — 15% evidence | 14.3/20 RS sector 0.2% · RS bench 30.6% · 1Y 124.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 11.6 + 8.6 + 14.3 = 55.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Broadcom Inc.AVGO | 54.9/100Mixed-positive evidence81% evidence | ASLEEP | 24.6/35 Revenue 32.3% · PAT 100% · OPM change 9.8 pp 83% evidence | 15.3/25 ROCE 7.1% · OPM 48.6% 76% evidence | 5.7/20 P/E 70.2× · PEG 5.05 65% evidence | 9.3/20 RS sector -23.6% · RS bench 4.9% · 1Y 37.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 15.3 + 5.7 + 9.3 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Analog Devices, Inc.ADI | 54.9/100Mixed-positive evidence81% evidence | ASLEEP | 20.6/35 Revenue 29.8% · PAT 81% · OPM change 12.4 pp 83% evidence | 13.9/25 ROCE 3.1% · OPM 38.1% 76% evidence | 11.8/20 P/E 58.5× · PEG 1.32 65% evidence | 8.6/20 RS sector -18.5% · RS bench 8.7% · 1Y 69.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.9 + 11.8 + 8.6 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Monolithic Power Systems, Inc.MPWR | 51.4/100Thin evidence · provisional56% evidence | ASLEEP | 20.1/35 Revenue — · PAT — · OPM change 3.5 pp 39% evidence | 15.8/25 ROCE 7.8% · OPM 30% 76% evidence | 9.4/20 P/E 84.6× · PEG — 15% evidence | 6.1/20 RS sector -21.1% · RS bench 4.9% · 1Y 66%6 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 15.8 + 9.4 + 6.1 = 51.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Marvell Technology, Inc.MRVL | 50.7/100Mixed-positive evidence64% evidence | LEADER | 14.5/35 Revenue 34.1% · PAT — · OPM change -0.3 pp 62% evidence | 7.2/25 ROCE 1.6% · OPM 14% 76% evidence | 10.3/20 P/E 56.5× · PEG — 15% evidence | 18.7/20 RS sector 27.7% · RS bench 58.7% · 1Y 182.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 7.2 + 10.3 + 18.7 = 50.7 · Decision use: Price leads the evidence: RS versus the benchmark is 58.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13NXP Semiconductors N.V.NXPI | 49.6/100Thin evidence · provisional56% evidence | ASLEEP | 20.5/35 Revenue — · PAT — · OPM change 21.8 pp 39% evidence | 15.1/25 ROCE 4.9% · OPM 47.3% 76% evidence | 11.2/20 P/E 23.6× · PEG — 15% evidence | 2.8/20 RS sector -33.7% · RS bench -9.9% · 1Y 14.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 15.1 + 11.2 + 2.8 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Arm Holdings plcARM | 48.9/100Thin evidence · provisional56% evidence | LEADER | 13.7/35 Revenue — · PAT — · OPM change -3.6 pp 39% evidence | 9.1/25 ROCE 1% · OPM 29.4% 76% evidence | 8.7/20 P/E 365.5× · PEG — 15% evidence | 17.4/20 RS sector 8.7% · RS bench 38.8% · 1Y 102.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 9.1 + 8.7 + 17.4 = 48.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Tower Semiconductor Ltd.TSEM | 47.8/100Mixed-negative evidence66% evidence | TURNING | 16.4/35 Revenue 10.6% · PAT 20.5% · OPM change 6.4 pp 53% evidence | 11.7/25 ROCE 2.1% · OPM 15.6% 57% evidence | 6.1/20 P/E 81.6× · PEG 4.35 65% evidence | 13.6/20 RS sector 16.1% · RS bench 45.1% · 1Y 397%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 11.7 + 6.1 + 13.6 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 45.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Microchip Technology IncorporatedMCHP | 47.2/100Mixed-negative evidence61% evidence | FADING | 18.6/35 Revenue 7.1% · PAT — · OPM change 26.9 pp 40% evidence | 9.9/25 ROCE 1.6% · OPM 16.6% 57% evidence | 13.7/20 P/E 293.7× · PEG 0.78 65% evidence | 5.0/20 RS sector -26.4% · RS bench -0.8% · 1Y 30.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 9.9 + 13.7 + 5 = 47.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ON Semiconductor CorporationON | 43.3/100Thin evidence · provisional53% evidence | FADING | 21.6/35 Revenue — · PAT — · OPM change 36.2 pp 32% evidence | 5.4/25 ROCE -0.5% · OPM -3.5% 76% evidence | 10.6/20 P/E 44.1× · PEG — 15% evidence | 5.7/20 RS sector -19.4% · RS bench 4.5% · 1Y 69.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 5.4 + 10.6 + 5.7 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18STMicroelectronics N.V.STM | 42.7/100Thin evidence · provisional56% evidence | FADING | 17.6/35 Revenue — · PAT — · OPM change 2.2 pp 39% evidence | 6.0/25 ROCE 0.8% · OPM 2.3% 76% evidence | 9.1/20 P/E 139× · PEG — 15% evidence | 10.0/20 RS sector -0.8% · RS bench 25.3% · 1Y 115.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 6 + 9.1 + 10 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19SiTime CorporationSITM | 42.5/100Thin evidence · provisional51% evidence | FADING | 20.2/35 Revenue 65.2% · PAT — · OPM change 35.7 pp 40% evidence | 5.5/25 ROCE -1.2% · OPM -10.9% 57% evidence | 9.3/20 P/E 98.7× · PEG — 15% evidence | 7.5/20 RS sector -2.7% · RS bench 24.4% · 1Y 192.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 5.5 + 9.3 + 7.5 = 42.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Qorvo, Inc.this pageQRVO | 41.9/100Thin evidence · provisional56% evidence | TURNING | 16.2/35 Revenue — · PAT — · OPM change 0.7 pp 39% evidence | 7.1/25 ROCE 1.9% · OPM 3.9% 76% evidence | 11.4/20 P/E 21.8× · PEG — 15% evidence | 7.2/20 RS sector -29.9% · RS bench -2.8% · 1Y 7.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 7.1 + 11.4 + 7.2 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Intel CorporationINTC | 41.6/100Thin evidence · provisional56% evidence | FADING | 15.9/35 Revenue — · PAT — · OPM change -20.7 pp 39% evidence | 4.7/25 ROCE 1.1% · OPM -23.1% 76% evidence | 8.5/20 P/E 3550× · PEG — 15% evidence | 12.5/20 RS sector 23.8% · RS bench 51.4% · 1Y 406%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 4.7 + 8.5 + 12.5 = 41.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Rambus Inc.RMBS | 40.0/100Thin evidence · provisional56% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -3.6 pp 39% evidence | 14.3/25 ROCE 5% · OPM 34.3% 76% evidence | 10.1/20 P/E 60.9× · PEG — 15% evidence | 1.1/20 RS sector -36.1% · RS bench -13.7% · 1Y 38%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.3 + 10.1 + 1.1 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23MACOM Technology Solutions Holdings, Inc.MTSI | 39.4/100Mixed-negative evidence66% evidence | FADING | 17.3/35 Revenue — · PAT — · OPM change 2.8 pp 39% evidence | 11.6/25 ROCE 2.9% · OPM 17.6% 76% evidence | 4.2/20 P/E 103.2× · PEG 5.61 65% evidence | 6.3/20 RS sector -14.7% · RS bench 9.6% · 1Y 126%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.6 + 4.2 + 6.3 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24QUALCOMM IncorporatedQCOM | 38.5/100Thin evidence · provisional56% evidence | ASLEEP | 12.6/35 Revenue — · PAT — · OPM change -6.6 pp 39% evidence | 13.1/25 ROCE 3.5% · OPM 21.8% 76% evidence | 11.3/20 P/E 21.9× · PEG — 15% evidence | 1.5/20 RS sector -36.4% · RS bench -12.8% · 1Y 10.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 13.1 + 11.3 + 1.5 = 38.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25GLOBALFOUNDRIES Inc.GFS | 38.5/100Thin evidence · provisional51% evidence | FADING | 14.9/35 Revenue 0.8% · PAT — · OPM change 1.5 pp 40% evidence | 9.6/25 ROCE 1.3% · OPM 11% 57% evidence | 10.9/20 P/E 32× · PEG — 15% evidence | 3.1/20 RS sector -24.6% · RS bench -2.3% · 1Y 61.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 9.6 + 10.9 + 3.1 = 38.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Semtech CorporationSMTC | 38.3/100Mixed-negative evidence64% evidence | FADING | 10.7/35 Revenue 14.3% · PAT — · OPM change -5.4 pp 62% evidence | 7.3/25 ROCE 2.2% · OPM 8.9% 76% evidence | 9.0/20 P/E 218.7× · PEG — 15% evidence | 11.3/20 RS sector -1.7% · RS bench 26.7% · 1Y 154%11 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 7.3 + 9 + 11.3 = 38.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Skyworks Solutions, Inc.SWKS | 38.0/100Thin evidence · provisional56% evidence | ASLEEP | 13.6/35 Revenue — · PAT — · OPM change -7 pp 39% evidence | 7.5/25 ROCE 0.7% · OPM 4.5% 76% evidence | 10.8/20 P/E 32.4× · PEG — 15% evidence | 6.1/20 RS sector -35.7% · RS bench -9.9% · 1Y -6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 7.5 + 10.8 + 6.1 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Qorvo, Inc.'s stock price today?
Qorvo, Inc. trades at $95.0, +13.0% over the past year. The company is valued at $8.0 B. The stock sits at 61% of its 52-week range of $77–$106, +9.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 2 weeks in. — as of 5 August 2026.
What were Qorvo, Inc.'s latest quarterly results?
Qorvo, Inc. reported revenue of $0.8 B and net profit of $0.0 B for the Mar 26 quarter. Revenue fell 6.9% and profit rose 0.0% year on year. Earnings per share were $0.32. The operating margin was 3.7%, 0.3 pp higher than a year earlier. — as of 5 August 2026.
What is Qorvo, Inc.'s revenue?
Qorvo, Inc. reported revenue of $0.8 B in the Mar 26 quarter, −6.9% year on year. For the full FY26 fiscal year, revenue was $3.7 B (−1.1%). Over the last 4 years revenue compounded at −5.7% a year. — as of 5 August 2026.
What is Qorvo, Inc.'s profit?
Qorvo, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was $0.3 B. The operating margin ran 3.7% in the latest quarter. — as of 5 August 2026.
What is Qorvo, Inc.'s market cap?
Qorvo, Inc.'s market capitalisation is $8.0 B at a stock price of $95.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Qorvo, Inc. pay a dividend?
No — Qorvo, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Qorvo, Inc. growing?
The picture is mixed for Qorvo, Inc.: latest-quarter revenue −6.9% year on year, profit +0.0%, and the margin +0.3 pp at 3.7%. The 4-year compound rates are −5.7% (revenue) and −24.2% (profit). The earnings engine currently reads: mixed — as of 5 August 2026.
How is Qorvo, Inc. performing?
Qorvo, Inc. is in a confirmed uptrend, 2 weeks in. Its latest quarter's revenue fell 6.9% and profit rose 0.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
Is Qorvo, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 2 of stage 2), trading +9.2% versus its 200-day average and at 61% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Qorvo, Inc. beating the market?
On recent form, yes — Qorvo, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +70% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Qorvo, Inc.'s stock price go up?
This page publishes no price forecast for Qorvo, Inc. What it measures instead: the stock price is $95.0, the price is in a confirmed uptrend 2 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Qorvo, Inc.?
Somewhat — short interest is 8.5% of Qorvo, Inc.'s tradable float, about 5.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Qorvo, Inc. have too much debt?
It is moderate — Qorvo, Inc.'s debt-to-equity is 0.45. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Qorvo, Inc.'s capex?
Qorvo, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.1 B. — as of 5 August 2026.
What is Qorvo, Inc.'s cash flow?
Qorvo, Inc. generated $0.8 B of operating cash flow in FY26 and $0.7 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Qorvo, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 454% of Qorvo, Inc.'s reported profit arrived as operating cash. In FY26, operating cash was $0.8 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Qorvo, Inc.?
On the balance sheet, the Z-score reads 3.31 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Qorvo, Inc. in its business cycle?
Qorvo, Inc.'s FY26 operating margin was 11.1%, against a 5-year band of 2.4%–26.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 3.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Qorvo, Inc. story?
The sharpest disagreement: annual EPS moved +524.1% against a +13.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Qorvo, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Qorvo, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.